Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RAGE signaling inhibition prevents the malignant phenotypes of pancreatic ductal adenocarcinoma cells.

Scientific reports - 15 Apr 2026

Minami Hironori, Munesue Seiichi, Araki Takahiro, Tokoro Tomokazu, Takei Ryohei, Takada Satoshi, Okazaki Mitsuyoshi, Nakanuma Shinichi, Makino Isamu, Yamamoto Yasuhiko, Yagi Shintaro

Abstract excerpt

Receptor for advanced glycation end-products (RAGE) is implicated in immune and inflammatory diseases as well as the malignant phenotypes of cancer. Blocking RAGE signaling is thought to reduce its impact on disease states. In this study, we investigated the effect of RAGE signaling inhibitors (inhRAGE) on the malignant phenotypes of pancreatic ductal adenocarcinoma (PDAC). Four PDAC cell lines were used....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal
Share to Cell Movement

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Proliferation

Share to HMGB1 Protein

Share to Mice, Nude

Share to Pancreatic Neoplasms

Share to Receptor for Advanced Glycation End Products

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 41986643
DOI: 10.1038/s41598-026-48913-5
PMCID: PMC13243639

Genes

HMGB1
S100B

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAGE signaling inhibition prevents the malignant phenotypes of pancreatic ductal adenocarcinoma cells.PMID 41986643Read ↗

RhoGDI2 induced malignant phenotypes of pancreatic cancer cells via regulating Snail expression.Semantic proximity Read ↗

The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survivalSemantic proximity Read ↗

Blockades Adenosine Receptor 2B Suppresses Pancreatic Adenocarcinoma Progression by Inhibiting Leukemia Inhibitory Factor Secretion from MacrophagesSemantic proximity Read ↗

TNFR2 mediates pancreatic cancer proliferation, migration, and invasion via the NF‑κB signaling pathwaySemantic proximity Read ↗

Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancerSemantic proximity Read ↗

Expression of oncogenic K-ras and loss of Smad4 cooperate to induce the expression of EGFR and to promote invasion of immortalized human pancreas ductal cells.Semantic proximity Read ↗

WITHDRAWN: Exogenous HMGB1 promotes pancreatic cancer progression by supporting the crosstalk between tumor and myeloid-derived suppressor cellSemantic proximity Read ↗

Molecular Characteristics of RAGE and Advances in Small-Molecule InhibitorsSemantic proximity Read ↗

HMGB1, S100 proteins and other RAGE ligands in cancer - markers, mediators and putative therapeutic targets.Semantic proximity Read ↗

Growth Hormone Receptor Antagonist Markedly Improves Gemcitabine Response in a Mouse Xenograft Model of Human Pancreatic CancerSemantic proximity Read ↗

The use of GEM models for experimental cancer therapeuticsSemantic proximity Read ↗

Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.